Simcere Pharmaceutical Group Ltd
HKEX:2096

Watchlist Manager
Simcere Pharmaceutical Group Ltd Logo
Simcere Pharmaceutical Group Ltd
HKEX:2096
Watchlist
Price: 11.42 HKD 0.53% Market Closed
Market Cap: HK$29.6B

Relative Value

The Relative Value of one Simcere Pharmaceutical Group Ltd stock under the Base Case scenario is hidden HKD. Compared to the current market price of 11.42 HKD, Simcere Pharmaceutical Group Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Simcere Pharmaceutical Group Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Simcere Pharmaceutical Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
28.3B HKD 3.5 28.6 19.3 19.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 57 38.2 40.9
US
Johnson & Johnson
NYSE:JNJ
566.4B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
287.9B CHF 4.7 30.7 12.9 15.1
US
Merck & Co Inc
NYSE:MRK
297.4B USD 4.6 15.6 11 13
CH
Novartis AG
SIX:NOVN
229.6B CHF 5.3 20.5 12.9 16.6
UK
AstraZeneca PLC
LSE:AZN
215B GBP 5.1 31.6 15.1 22.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.6
US
Pfizer Inc
NYSE:PFE
151.8B USD 2.4 15.5 7.8 10.7
FR
Sanofi SA
PAR:SAN
98.9B EUR 1.8 8.3 7.7 7.7
P/E Multiple
Earnings Growth PEG
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average P/E: 24.2
28.6
35%
0.8
US
Eli Lilly and Co
NYSE:LLY
57
54%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.1
6%
3.5
CH
Roche Holding AG
SIX:ROG
30.7
29%
1.1
US
Merck & Co Inc
NYSE:MRK
15.6
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
17%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
2%
6.6
US
Pfizer Inc
NYSE:PFE
15.5
27%
0.6
FR
Sanofi SA
PAR:SAN
8.3
1%
8.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average EV/EBITDA: 43.8
19.3
15%
1.3
US
Eli Lilly and Co
NYSE:LLY
38.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
US
Merck & Co Inc
NYSE:MRK
11
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
1%
9.2
US
Pfizer Inc
NYSE:PFE
7.8
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Simcere Pharmaceutical Group Ltd
HKEX:2096
Average EV/EBIT: 91.8
19.3
20%
1
US
Eli Lilly and Co
NYSE:LLY
40.9
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
18
6%
3
CH
Roche Holding AG
SIX:ROG
15.1
6%
2.5
US
Merck & Co Inc
NYSE:MRK
13
8%
1.6
CH
Novartis AG
SIX:NOVN
16.6
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
0%
N/A
US
Pfizer Inc
NYSE:PFE
10.7
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3